Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
41 studies found for:    triple negative breast cancer | Phase 3, 4
Show Display Options
Rank Status Study
1 Active, not recruiting Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
Conditions: Breast Tumor;   Breast Cancer;   Cancer of the Breast;   Estrogen Receptor- Negative Breast Cancer;   HER2- Negative Breast Cancer;   Progesterone Receptor- Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer;   Triple-negative Metastatic Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: nab-Paclitaxel 125 mg/m2;   Drug: Carboplatin AUC 2;   Drug: gemcitabine 1000 mg
2 Not yet recruiting PCI in Advanced Triple Negative Breast Cancer Patients Who Response to 1st Line Chemotherapy
Conditions: Breast Cancer;   Brain Metastasis
Intervention: Radiation: prophylactic cranial irradiation
3 Recruiting Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer
Conditions: Breast Cancer;   Capecitabine;   Triple Negative Breast Cancer
Intervention:
4 Active, not recruiting A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Interventions: Drug: Veliparib;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Placebo
5 Recruiting Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: 5-Fu/epirubicin/CTX following Docetaxel;   Drug: Docetaxel/capecitabine followed by XEC
6 Active, not recruiting Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer
Condition: Triple Negative Breast Cancer
Intervention: Drug: Zoledronic acid
7 Recruiting Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)
Condition: Triple Negative Breast Cancer (TNBC)
Interventions: Biological: Pembrolizumab;   Drug: Nab-paclitaxel;   Drug: Paclitaxel;   Drug: Gemcitabine;   Drug: Carboplatin;   Drug: Normale Saline Solution
8 Recruiting Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
Condition: Metastatic Triple Negative Breast Cancer
Interventions: Biological: pembrolizumab;   Drug: capecitabine;   Drug: eribulin;   Drug: gemcitaine;   Drug: vinorelbine
9 Not yet recruiting A Phase III Trial of Carboplatin as Adjuvant Chemotherapy in Triple Negative Breast Cancer
Condition: Breast Cancer
Intervention: Drug: carboplatin
10 Recruiting TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature
Conditions: Triple Negative Breast Cancer;   Breast Cancer
Interventions: Drug: docetaxel;   Drug: doxorubicin or epirubicin;   Drug: cyclophosphamide;   Drug: gemcitabine;   Drug: cisplatin
11 Recruiting Huaier Granule in Treating Women With Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Intervention: Drug: Huaier Granule
12 Recruiting A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple Negative Breast Cancer (IMpassion130)
Condition: Metastatic Breast Cancer, Triple Negative Breast Cancer
Interventions: Drug: Atezolizumab [TECENTRIQ];   Drug: Nab-Paclitaxel;   Drug: Placebo
13 Recruiting Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer
Condition: Breast Cancer
Intervention:
14 Completed Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC)
Condition: Breast Cancer
Interventions: Drug: Gemcitabine,cisplatin;   Drug: Gemcitabine, Paclitaxel
15 Recruiting Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)
Condition: Breast Cancer
Interventions: Drug: taxane plus carboplatin;   Drug: Taxane
16 Recruiting Adjuvant Treatment of EC Followed by wP and wPCb in Triple-Negative Breast Cancer
Condition: Breast Neoplasm
Interventions: Drug: Epirubicin plus Cyclophosphamide;   Drug: Paclitaxel;   Drug: Paclitaxel plus Carboplatin
17 Recruiting Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1
Condition: Invasive Ductal Breast Carcinoma
Interventions: Drug: Carboplatin;   Drug: Abraxane;   Drug: MPDL3280A;   Procedure: Surgery;   Drug: Anthra
18 Recruiting Efficacy of Capecitabine Metronomic Chemotherapy to Triple-negative Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Capecitabine
19 Recruiting Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer
Condition: Female Breast Cancer
Intervention: Drug: Toremifene; Anastrozole
20 Recruiting Pilot Study of Durvalumab (MEDI4736) in Combination With Vigil™ in Advanced Breast Cancer
Condition: Triple Negative Breast Cancer
Interventions: Biological: Vigil™;   Drug: Durvalumab (MEDI4736)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years